Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...

Full description

Bibliographic Details
Main Authors: Carolina Valeria Mahuad, Maria de los Ángeles Vicente Repáraz, Marta E. Zerga, María Florencia Aizpurúa, Claudia Casali, Gonzalo Garate
Format: Article
Language:English
Published: SAGE Publishing 2016-06-01
Series:Rare Tumors
Subjects:
Lymphoma
large-cell
anaplastic
anaplastic lymphoma kinase
crizotinib
Online Access:http://www.pagepress.org/journals/index.php/rt/article/view/6266

Internet

http://www.pagepress.org/journals/index.php/rt/article/view/6266

Similar Items